Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNOVATE study of oral VH4524184 regimens in treatment-naive adults with HIV-1
2025-521918-26-00Phase 2Authorised
- Sponsor
- ViiV Healthcare
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of VH4524184 in Human immunodeficiency virus infection type 1 (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Plasma HIV-1 RNA <50 copies/mL (FDA snapshot) at Month 12. Planned start Feb 2026; status: authorised.
02
Drugs
VH4524184
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2025-521918-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521918-26-00.